These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831 [TBL] [Abstract][Full Text] [Related]
24. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol. Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876 [TBL] [Abstract][Full Text] [Related]
26. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716 [TBL] [Abstract][Full Text] [Related]
27. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. Di Taranto MD; D'Agostino MN; Fortunato G Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):979-87. PubMed ID: 26165249 [TBL] [Abstract][Full Text] [Related]
28. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992 [TBL] [Abstract][Full Text] [Related]
29. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731 [TBL] [Abstract][Full Text] [Related]
30. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Marais AD; Kim JB; Wasserman SM; Lambert G Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268 [TBL] [Abstract][Full Text] [Related]
31. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Maxwell KN; Breslow JL Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856 [TBL] [Abstract][Full Text] [Related]
32. PCSK9: a key modulator of cardiovascular health. Seidah NG; Awan Z; Chrétien M; Mbikay M Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727 [TBL] [Abstract][Full Text] [Related]
33. The genetic spectrum of familial hypercholesterolemia in Pakistan. Ahmed W; Whittall R; Riaz M; Ajmal M; Sadeque A; Ayub H; Qamar R; Humphries SE Clin Chim Acta; 2013 Jun; 421():219-25. PubMed ID: 23535506 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of familial hypercholesterolaemia. Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791 [TBL] [Abstract][Full Text] [Related]
35. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270 [TBL] [Abstract][Full Text] [Related]
36. [Molecular basis of familial hypercholesterolemia-like phenotype heterogeneity]. Wang LY; Lin J; Liu S; Chen BS Yi Chuan Xue Bao; 2005 Jul; 32(7):770-7. PubMed ID: 16078748 [TBL] [Abstract][Full Text] [Related]
37. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis. Kwon M; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo J; Hur SH; Jeong JO; Jang Y; Lee SH; Lee JH Atherosclerosis; 2015 Sep; 242(1):8-12. PubMed ID: 26160041 [TBL] [Abstract][Full Text] [Related]
39. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719 [TBL] [Abstract][Full Text] [Related]
40. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Costet P; Krempf M; Cariou B Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]